Search results for "Obstructive"

showing 10 items of 609 documents

Airway inflammation in patients affected by obstructive sleep apnea syndrome

2004

Obstructive sleep apnea syndrome (OSAS) has been shown to be associated to upper airway inflammation. The object of the present study was to establish the presence of bronchial inflammation in OSAS subjects. In 16 subjects affected by OSAS, and in 14 healthy volunteers, airway inflammation was detected by the cellular analysis of the induced sputum. OSAS patients, as compared to control subjects, showed a higher percentage of neutrophils (66.7+/-18.9 vs. 25.8+/-15.6) (P<0.001) and a lower percentage of macrophages (29.4+/-18.4 vs. 70.8+/-15.3) (P<0.001). The percentage of eosinophils and lymphocytes were not significantly different in the two groups. OSAS subjects show bronchial inflammatio…

MalePulmonary and Respiratory MedicineNeutorphilSputum Cytologymedicine.medical_specialtyPathologyNeutrophilsInflammationGranulocyteGastroenterologyBody Mass IndexLeukocyte CountInternal medicinemedicineHumansInduced sputumBronchitisAgedSleep Apnea Obstructivebusiness.industryMacrophagesSputumSleep apneaOSASMiddle Agedmedicine.diseaserespiratory tract diseasesObstructive sleep apneamedicine.anatomical_structureNeutrophil InfiltrationOSAS; Neutrophils; Induced sputumBronchitisSputumFemalemedicine.symptombusinessBody mass index
researchProduct

Upregulation of basic fibroblast growth factor in smokers with chronic bronchitis

2006

The aim of the study was to investigate the expression of basic fibroblast growth factor (bFGF) and its receptor, fibroblast growth factor receptor (FGFR)-1, in the central airways of smokers with chronic bronchitis. The lobar bronchi from 17 subjects undergoing thoracotomy for solitary nodules were examined. All had a history of cigarette smoking, nine had symptoms of chronic bronchitis and airflow limitation, and eight were asymptomatic with normal lung function. Using immunohistochemical methods, bFGF and FGFR-1 expression in the total airway wall and the different airway compartments, i.e. bronchial glands, submucosal vessels and smooth muscle, was quantified. Moreover, to investigate t…

MalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyChronic bronchitisAngiogenesisBasic fibroblast growth factorFibroblast growth factorchemistry.chemical_compoundGrowth factor receptorCigarette smokingHumansMedicineAgedFibrolast growth factor receptor-1business.industryChronic obstructive pulmonary diseaseFibroblast growth factor receptor 1Smokingrespiratory systemmedicine.diseaseAirway remodelling; cigarette smoking; chronic obstructive pulmonary disease; fibroblast growth factor receptor-1Airway remodellingUp-Regulationrespiratory tract diseasesBronchitis ChronicchemistryFibroblast growth factor receptorBronchitisFemaleFibroblast Growth Factor 2Airway remodelling; Chronic obstructive pulmonary disease; Cigarette smoking; Fibrolast growth factor receptor-1;business
researchProduct

Correlates of mortality in elderly COPD patients: focus on health-related quality of life

2009

BACKGROUND AND OBJECTIVE: The Saint George Respiratory Questionnaire (SGRQ) is widely used as a measure of health-related quality of life (HRQL) in patients with COPD. This study tested whether the SGRQ predicts the survival of patients with COPD. METHODS: The study recruited 238 patients with COPD who were participants in the multicentre Salute Respiratoria nell'Anziano (Sa.R.A.) study. Patients' sociodemographic, clinical and functional characteristics were assessed and the association between the SGRQ and mortality, corrected for potential confounders, was estimated. RESULTS: The mean age of study participants was 72.6 years. Over the 5-year observation period there were 88 deaths. After…

MalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyCopd patientsSettore MED/10 - Malattie Dell'Apparato RespiratorioRisk AssessmentSeverity of Illness IndexPulmonary Disease Chronic ObstructiveQuality of lifePredictive Value of TestsSurveys and QuestionnairesHumansMedicineAgedProportional Hazards ModelsHealth related quality of lifeCOPDbusiness.industryHazard ratioConfoundingPrognosismedicine.diseaseHealth SurveysCOPD mortality health-related quality of life.Confidence intervalItalyQuality of LifeFemalebusinessLower mortality
researchProduct

The ‘real-life’ COPD patient in Germany: The DACCORD study

2016

Abstract Introduction DACCORD is an ongoing, longitudinal, non-interventional study within the German COPD National Prospective Registry. This manuscript describes the baseline characteristics of the first 5924 participants, recruited between November 2012 and November 2013. Methods The main inclusion criteria are a physician diagnosis of COPD, age ≥40 years, and initiating or changing COPD maintenance medication. Data collected included: Demographic and disease characteristics; prescribed medication; symptoms; COPD Assessment Test (CAT); modified Medical Research Council dyspnoea score (mMRC); exacerbations; comorbidities; and forced expiratory volume in 1 s (FEV 1 ). Results Approximately…

MalePulmonary and Respiratory MedicineRegistryPediatricsmedicine.medical_specialtyPopulationComorbiditySeverity of Illness IndexPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineBaselineForced Expiratory VolumeGermanyCOPDHumansMedicineProspective StudiesRegistries030212 general & internal medicineeducationObservationalAgededucation.field_of_studyCOPDPrimary Health Carebusiness.industryMiddle AgedExertional dyspnoeamedicine.diseaseComorbidityRegimenTreatment Outcome030228 respiratory systemSpirometryBaseline characteristicsFemaleDisease characteristicsObservational studybusinessRespiratory Medicine
researchProduct

Bronchodilatory Effect of Deep Inspiration Is Absent in Subjects With Mild COPD

2004

Study objectives To investigate whether the bronchodilatory effect of deep inspiration is impaired in subjects with COPD. Methods We measured deep inspiration-induced bronchodilation in 19 patients with COPD and 17 healthy subjects (mean age, 67.8 ± 7.1 years vs 62.5 ± 9.3 years, respectively [± SEM]). Each subject underwent a series of single-dose methacholine provocations to induce at least a 15% reduction in inspiratory vital capacity (IVC). When this was achieved, subjects were asked to perform four consecutive deep inspirations, after which the IVC measurement was repeated and the percentage of bronchodilation by deep inspiration was calculated. Results The percentage of reduction in I…

MalePulmonary and Respiratory MedicineSpirometryAgingVital CapacitySettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineSensitivity and Specificitylung function COPDBronchial Provocation TestsStatistics NonparametricPulmonary Disease Chronic ObstructiveReference ValuesForced Expiratory VolumeBronchodilationmedicineHumansLung volumesMethacholine ChlorideAgedProbabilityAged 80 and overCOPDmedicine.diagnostic_testPulmonary Gas Exchangebusiness.industryMiddle AgedAirway obstructionPrognosismedicine.diseaserespiratory tract diseasesBronchodilatationInhalationSpirometryCase-Control StudiesAnesthesiaRespiratory MechanicsFemaleBronchoconstrictionMethacholinemedicine.symptomLung Volume MeasurementsCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: The DACCORD observational study

2017

Abstract Introduction DACCORD is an observational, non-interventional study being conducted in German primary and secondary care centres. The study aims to describe the impact of disease (including exacerbations) and treatments over 2 years on ‘real-life' patients with chronic obstructive pulmonary disease (COPD). Materials and methods Patients had a clinical and spirometry diagnosis of COPD, were aged ≥40 years and, on recruitment, were initiating or changing COPD maintenance medication. The only exclusion criteria were asthma and randomised clinical trial participation. Exacerbations data were collected every 3 months. COPD medication, COPD Assessment Test (CAT) and forced expiratory volu…

MalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyPediatricsExacerbationPopulationPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineForced Expiratory VolumeGermanyEpidemiologymedicineHumansddc:610030212 general & internal medicineeducationLungAgedAsthmaAged 80 and overCOPDeducation.field_of_studymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseasePatient Outcome AssessmentClinical trial030228 respiratory systemSpirometryDisease ProgressionFemaleObservational studySelf ReportbusinessFollow-Up StudiesRespiratory Medicine
researchProduct

Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD

2011

SummaryForced inspiratory measures have been described to reflect the reduction in dyspnoea upon bronchodilation in severe COPD. Based on this we evaluated the applicability and usefulness of a portable device for the assessment of forced inspiration. In 37 patients with COPD (GOLD II/II/IV n = 16/15/6, mean ± SD FEV1 46.2 ± 15.4%pred) lung function was recorded prior to inhalation of 24 μg formoterol and 30 min later. Assessments comprised spirometry including forced inspiration, body plethysmography, maximum inspiratory flow (InCheck, Clement Clarke), and changes in dyspnoea via visual analogue scale (VAS). The sequence was repeated on a second day to assess reproducibility. Bronchodilati…

MalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyPortable deviceVisual analogue scalePeak inspiratory flowPulmonary Disease Chronic ObstructiveForced inspirationInternal medicineDyspnoeaBronchodilationCOPDHumansMedicinePlethysmographPeak flow meterMonitoring Physiologicmeasurement_unitAnalysis of VarianceCOPDmedicine.diagnostic_testbusiness.industrymedicine.diseaserespiratory tract diseasesBronchodilatationDyspneaSpirometrymeasurement_unit.measuring_instrumentPhysical therapyCardiologyBronchodilationFemaleFormoterolbusinessInspiratory Capacitymedicine.drugRespiratory Medicine
researchProduct

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with mod…

2015

Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. Methods This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ≥40 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% to <80% predicted) to QVA149 110/50 µg o.d. or TIO 18 µg o…

MalePulmonary and Respiratory MedicineVital capacitymedicine.drug_classChronic Obstructive Pulmonary DiseaseVital CapacityScopolamine DerivativesQuinolonesCOPD PharmacologyDrug Administration SchedulePulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodQuality of lifeForced Expiratory VolumeFormoterol FumarateBronchodilatorHumansMedicine1506Tiotropium BromideAdrenergic beta-2 Receptor AgonistsAgedCOPDbusiness.industryMiddle Agedmedicine.diseaseGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeEthanolaminesBronchodilator AgentsAnesthesiaIndansQuality of LifeIndacaterolFemaleFormoterolbusinessmedicine.drugThorax
researchProduct

Similarity and differences in elderly patients with fixed airflow obstruction by asthma and by chronic obstructive pulmonary disease

2008

SummaryBackgroundEpidemiologic studies have demonstrated that elderly patients with fixed airflow obstruction can be affected by asthma or chronic obstructive pulmonary disease (COPD).MethodsWe studied 49 consecutive elderly outpatients, presenting fixed airflow obstruction, by clinical history (smoking), pulmonary function tests, blood gas analysis, and induced sputum.ResultsThe age was not different in patients with COPD (n=28) and asthma (n=21) (70.2±3.9 years vs. 69.6±3.7 years), also the degree of fixed airflow obstruction was similar (FEV1: 58.3±1.5% vs. 59.0±1.4% of predicted). Patients with asthma had significantly more eosinophils in peripheral blood (0.43±0.05×10−3μL vs. 0.27±0.1×…

MalePulmonary and Respiratory MedicineVital capacitymedicine.medical_specialtySettore MED/09 - Medicina Internaasthma chronic obstructive pulmonary disease.NeutrophilsVital Capacitychronic obstructive pulmonary disease.GastroenterologyPulmonary function testingPulmonary Disease Chronic ObstructiveFEV1/FVC ratioElderlyDLCOForced Expiratory VolumeInternal medicinemedicineHumanselderly patients; fixed airflow obstruction; asthma; chronic obstructive pulmonary disease.AgedAsthmaCOPDEosinophil cationic proteinbusiness.industryChronic obstructive pulmonary diseasefixed airflow obstructionRespiratory diseaseSputumasthmamedicine.diseaseRespiratory Function Testselderly patientrespiratory tract diseasesSurgeryEosinophilsFemalebusinessRespiratory Medicine
researchProduct

Oral Sustained-Release Aminophylline and Bronchodilator Response to Inhaled Fenoterol in Patients with Chronic Airflow Obstruction

1985

The bronchodilator response to inhaled fenoterol (400 micrograms) was examined in the morning and in the afternoon before and during oral sustained-release aminophylline treatment in eight patients with chronic reversible airway obstruction. Bronchodilatation was evaluated by measuring serial peak expiratory flow rates (PEFR) for eight hours after inhaled fenoterol and calculating the area under the time-response curves and the percentage increment from the baseline values. The patients showed an enhancement of the bronchodilatation achieved with fenoterol in the morning during aminophylline treatment. In the afternoon, instead, the effect of the fenoterol was not improved by oral aminophyl…

MalePulmonary and Respiratory Medicinemedicine.drug_classPeak Expiratory Flow RateCritical Care and Intensive Care MedicineBronchodilatormedicineHumansLung Diseases ObstructiveFenoterolFenoterolMorningAerosolsInhalationbusiness.industryRespiratory diseaseMiddle Agedrespiratory systemAirway obstructionmedicine.diseaseAminophyllineBronchodilator AgentsBronchodilatationDelayed-Action PreparationsAnesthesiaDrug Therapy CombinationFemaleAminophyllineCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct